| August 1 |
Amgen Responds to Final CMS National Coverage Determination on Use
of Erythropoiesis-Stimulating Agents in Oncology |
| August 1 |
Sanofi-aventis First Half 2007: Solid Results in a Difficult
Context; |
| August 1 |
SurModics Acquires Brookwood Pharmaceuticals |
| August 1 |
Advanced Cell Technology Enters Into Definitive Merger Agreement
With Mytogen, Inc. |
| August 1 |
Teva Reports Second Quarter 2007 Results |
| August 1 |
Southern Research Institute Spinout, Brookwood Pharmaceuticals,
Acquired by SurModics for $62 Million |
| August 1 |
Cell Therapeutics, Inc. Completes Acquisition of SMi |
| August 1 |
Allergan Reports Second Quarter Operating Results |
| August 1 |
Court Takes Matter of Wyeth's Motion for Preliminary Injunction
Under Advisement; Obtains Agreement from Teva and Sun to Delay Any
Potential Launch of Generic Pantoprazole |
| August 1 |
Beijing Med-Pharm Announces That Alliance BMP Limited Has Received
MOFCOM Approval to Acquire Interest in Guangzhou Pharmaceutical
Corporation |
| August 1 |
Reorganisation of Astellas European Business Functions |
| August 1 |
Publicis Groupe Launches SSF Group |
| August 2 |
Genentech Announces Expiration of Hart-Scott-Rodino Waiting Period
and Completes Acquisition of Tanox |
| August 2 |
Anadys Pharmaceuticals Announces Strategic Restructuring and
Reports Second Quarter 2007 Financial Results |
| August 2 |
PharmaNet Development Group Agrees to Settle 2005 Securities Class
Action |
| August 2 |
New IMS Health Report Finds Generic Drugs Used More in Part D than
Commercial Market |
| August 2 |
Schering-Plough Announces Dissolution of Consent Decree |
| August 3 |
BIO Applauds Court of Appeals Decision |
| August 3 |
FDA, Defense Department Share Data to Enhance Medical Product
Safety Reviews |
| August 3 |
Regeneron and Bayer HealthCare Initiate Phase 3 Global Development
Program For VEGF Trap-Eye In Wet Age-Related Macular Degeneration
(AMD) |
| August 3 |
Novo Nordisk: Financial Statement for the Period 1 January 2007 to
30 June 2007 |
| August 3 |
A Voluntary Recall of a Specific Batch of “Vesanoid
Capsule,” a Treatment for Acute Promyelocytic Leukemia |
| August 3 |
Appeals Court Strikes Down D.C. Drug Price Control Law |
| August 3 |
Novo Nordisk Increased First Half-Year Operating Profit by 14% and
Raises the Expectation for 2007 Operating Profit Growth to Around
10% |
| August 3 |
GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First
North American Clinical Trials with GSK's Candidate Pre-pandemic
Flu Vaccine to Start. |
| August 3 |
Healthcare Acquisition Corp. and PharmAthene Receive Stockholder
Approval for Their Merger |
| August 6 |
Melior Discovery Enters New Pharmaceutical Collaboration |
| August 6 |
Santarus Reports Second Quarter 2007 Financial Results |
| August 6 |
Abbott Chief Operating Officer Richard A. Gonzalez to Retire |
| August 6 |
Novartis Concerned Indian Court Ruling Will Discourage Investments
in Innovation Needed to Bring Better Medicines to Patients |
| August 6 |
Buzz in Pharma Blogs This Week Includes Pfizer HIV Marketers
Getting Fired, FDA’s Hearing on Avandia, and Blogger Peter
Rost is Taking Over for Journalist Jim Edwards at Brandweek NRX |
| August 7 |
King Pharmaceuticals Reports Second-Quarter 2007 Financial Results |
| August 7 |
KineMed and Merck Enter Collaboration in Atherosclerosis |
| August 7 |
Pfizer Says Growth in Phase II Portfolio Supports Goal of Tripling
Phase III Portfolio by 2009 |
| August 7 |
Healthcare Acquisition Corp. and PharmAthene, Inc. File Certificate
of Merger to Complete Acquisition; Confirmation to Be Sought from
Delaware Court of Chancery Regarding Stockholder Vote |
| August 7 |
Bayer Continues On a Path of Growth |
| August 7 |
ADHD Appears to Be Associated with Depressed Dopamine Activity in
the Brain |
| August 7 |
Marketing Authorisation for the Antiretroviral Medicinal Product
Viracept is Suspended |
| August 7 |
Multicultural Marketing of Health and Wellness to Women. the Trend
Report Examines Ethnic & Demographic Differences in
Health-care-related Opinions and Behaviors |
| August 7 |
Asia Pacific to Replace United States and Europe as Pharmaceutical
Industry Powerhouse, Finds PricewaterhouseCoopers |
| August 7 |
Court Denies Terminally Ill Access to Experimental Drugs |
| August 8 |
Biovail Enters Into License and Development Agreement |
| August 8 |
Biovail Reports Second-Quarter 2007 Financial Results |
| August 8 |
AVI BioPharma Announces Refocused Clinical Development Strategy |
| August 8 |
Neuromed Announces that Merck & Co., Inc. Discontinues
Development of Pain Drug Candidate, Joint Research Program
Continues |
| August 8 |
Galapagos Announces Expanded Relationship with AstraZeneca |
| August 8 |
Bend Research and Pfizer Offer Proprietary Technology to Help Solve
Drug-Discovery Challenges |
| August 9 |
Shareholders Approve Peptech-EvoGenix Merger |
| August 9 |
Johnson & Johnson Statement on Civil Complaint Against The
American National Red Cross and Commercial Licensees |
| August 9 |
AVEO Announces Successful Completion of Discovery Agreement for
Novel Cancer Drugs |
| August 9 |
IBM Introduces "ePedigree" System to Combat Drug Counterfeiting and
Help Clients Comply With Regulations |
| August 9 |
WuXi PharmaTech (Cayman) Inc. Announces Pricing of Initial Public
Offering on NYSE |
| August 9 |
J&J Sues Red Cross Over Use of Red Cross Emblem |
| August 9 |
FDA - MedWatch - Prilosec (omeprazole), Nexium (esomeprazole)-
Early Communication About An Ongoing Safety Review |
| August 9 |
Health Canada Reviewing New Safety Information on Cardiac Events in
Patients Taking Losec (omeprazole) or Nexium (esomeprazole) |
| August 9 |
ImClone Systems Appoints John H. Johnson Chief Executive Officer |
| August 10 |
Bradley Pharmaceuticals Special Committee Receives Non-binding
Preliminary Bids |
| August 10 |
Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. Announce
Receipt of an FDA Action Letter for Bifeprunox, an Investigational
Treatment for Schizophrenia |
| August 10 |
NICE Responds to Judicial Review Outcome |
| August 10 |
Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study
of HCV-796 |
| August 10 |
This Week Pharmaceutical Blogs Discuss Departure of Managers from
Pfizer’s HIV Division, Approval of Selzentry, and Johnson
& Johnson Suing the Red Cross |
| August 10 |
Schering-Plough Corporation Prices Public Offering of Common Shares
and 6.00% Mandatory Convertible Preferred Stock |
| August 13 |
Roche and Actavis Agree on Product Transactions |
| August 13 |
TGA: Urgent Advice Regarding Management of Patients Taking
Lumiracoxib (Prexige) |
| August 13 |
Sanofi pasteur First Manufacturer to Ship Doses of Influenza
Vaccine for the 2007-2008 Season |
| August 13 |
Important Dear Healthcare Provider letter about pediatric dosing |
| August 15 |
Split off of CombiMatrix Corporation Completed Today on August 15,
2007 |
| August 15 |
Noven Completes Acquisition of JDS Pharmaceuticals |
| August 15 |
FDA Sends Warning Letter to Novartis Over Professional File Card |
| August 15 |
Epix Pharmaceuticals Achieves Discovery Milestone in Collaboration
with GlaxoSmithKline |
| August 16 |
Amgen Restructures Due to Lower Aranesp Revenues While Continuing
to Invest in Innovation and Future Growth |
| August 16 |
Baxter Awarded Pandemic Advanced Supply Contract from the
Department of Health |
| August 16 |
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma
Drug Zevalin from Biogen Idec for Sales and Marketing in the United
States |
| August 16 |
EvoGenix to Commence Second Project with GlaxoSmithKline |
| August 16 |
GlaxoSmithKline Signs Contract for Its Pandemic Flu Vaccine with UK
Government |
| August 16 |
Parion Sciences and Gilead Sciences Sign Agreement to Advance Drug
Candidates for Pulmonary Disease |
| August 16 |
Novartis Starts US Shipment of Fluvirin Allowing for Early
Influenza Vaccination of Millions of Americans |
| August 16 |
Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume
Clinical Trials for Xiaflex |
| August 16 |
NEJM Direct-to-Consumer Ad Study Shows Drug Industry Incapable of
Self- Regulation, Says AHF |
| August 16 |
New Clinical Trial Guidelines Reflect Northwick Park Lessons |
| August 16 |
Shanghai Century Acquisition Corporation Files Preliminary Proxy
Statement |
| August 16 |
FDA Approves Updated Warfarin (Coumadin) Prescribing Information |
| August 16 |
FDA Announces Baraclude (entecavir) is Not Recommended for HIV/HBV
Co-infected patients who are not also receiving HAART due to the
potential for the development of HIV resistance |
| August 16 |
Spherix Shareholders Support Company's Focus on Naturlose,
Biotechnology |
| August 17 |
Boston Scientific to Explore Sale of Cardiac Surgery and Vascular
Surgery Businesses |
| August 17 |
Layoffs at Amgen and Increase in DTC Advertising Are the Dominating
Topics in Pharmaceutical Blogs This Week |
| August 17 |
FDA Announces Use of Codeine Products by Some Breastfeeding Mothers
May Lead to Life-Threatening Side Effects in Nursing Babies |
| August 20 |
Alcon's Tender Offer Endorsed by WaveLight AG's Executive Committee
and Supervisory Board |
| August 20 |
Pharming Reports Positive Results in European Placebo-Controlled
Trial of Rhucin in Hereditary Angioedema |
| August 20 |
PDL BioPharma Announces Internal CEO Investigation Found No
Credible Evidence of Improper Personal Conduct or Breach of
Fiduciary Duty |
| August 20 |
MarkMonitor Brandjacking Index Exposes Online Scams That Threaten
Top Pharmaceutical Brands and Hurt Consumers |
| August 20 |
The Medical House PLC: Disposal of Needle-Free Insulin Injector
Business (the “Disposal”) |
| August 20 |
Chi-Med Announces Drug Discovery and Development Agreement with Eli
Lilly and Company |
| August 20 |
Mackler, Fisher, and Alta Communications Acquire HMP Communications |
| August 20 |
FDA Approves ImClone Systems' New State-of-the-Art Manufacturing
Facility |
| August 20 |
PCMA: Minnesota is First in the Nation to Require E-Prescribing |
| August 21 |
Medpace Strengthens Presence in Central Europe |
| August 22 |
United States District Court for the District of Arizona Grants
Roche's Motion for Preliminary Injunction |
| August 22 |
Pfizer Names Frank A. D'Amelio Chief Financial Officer |
| August 22 |
Prexige 200mg and 400mg Tablets to Be Withdrawn in New Zealand |
| August 22 |
Deltagen Reports 2007 Second Quarter Financial Results and
Announces a Restructuring |
| August 22 |
Roche Extends Tender Offer for Ventana |
| August 22 |
Ventana Responds to Second Extension of Roche's Unsolicited Tender
Offer |
| August 22 |
NICE Appraisal of Rituximab and Adalimumab for the Treatment of
Arthritis |
| August 22 |
NICE Recommends Natalizumab for the Treatment of Multiple Sclerosis |
| August 23 |
Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by
Regeneron and sanofi-aventis |
| August 23 |
GlaxoSmithKline Accelerates Review of Exelixis' XL880 |
| August 23 |
Abigail Alliance Will Appeal D.C. Circuit Court Decision |
| August 23 |
GPC Biotech Announces Restructuring |
| August 23 |
Clinical Data Acquires Epidauros Biotechnologie AG, Significantly
Enhancing Proprietary Genetic Biomarker Portfolio |
| August 23 |
Teijin and Chugai Enter an Agreement to Co-develop Ipsen's
Anti-diabetic Medicine in Japan |
| August 23 |
MedImmune Licenses Reverse Genetics Technology to Novartis for Use
in Influenza Vaccine Development and Production |
| August 23 |
Gene Logic Establishes Agreement with Merck Serono to Discover New
Development Paths for Multiple Clinical-Stage Drug Candidates |
| August 24 |
Flemming Lindeløv is Leaving the Lundbeck Supervisory Board |
| August 24 |
Study Finds Viagra Increases Release of Key Reproductive Hormone |
| August 27 |
Gene Logic and Solvay Pharmaceuticals Enter Agreement to Discover
New Development Paths for Multiple Clinical Drug Candidates |
| August 27 |
Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide
Collaboration on Metabolic Disorders Program |
| August 27 |
New 200 mg Vial for Eloxatin (Oxaliplatin Injection) Offers Greater
Convenience and Efficiency of Preparation |
| August 27 |
Neurochem Announces Results from Tramiprosate (Alzhemed) North
American Phase III Clinical Trial |
| August 27 |
This Week, Pharma Bloggers Discuss Pfizer’s New CFO, FDA
Studying Imagery in DTC ADS, Risperdal Approved for Children and
Teens, and Renewal of Chip |
| August 28 |
KineMed to Collaborate With Merck KgaA to Validate New Applications
for Drug Development Candidates |
| August 28 |
Human Genome Sciences Announces $40 Million Milestone Payment
Related to Albuferon Development |
| August 28 |
Curis Updates Research on Hedgehog Agonist Protein Program for
Cardiovascular Disease Indications |
| August 28 |
Multicultural Marketing of Health and Wellness to Women. the Trend
Report Examines Ethnic & Demographic Differences in
Health-care-related Opinions and Behaviors |
| August 28 |
Xoma Licenses Antibody Technology to Pfizer |
| August 28 |
Practicing What They Preach: GSK Announces Employee Wellness
Initiative |
| August 28 |
Statin Treatment May Curb Alzheimer's Brain Changes |
| August 28 |
FDA Approves Human Thrombin for Topical Use in Surgery |
| August 28 |
Sunesis Pharmaceuticals Announces Reorganization to Focus Resources
and Build Value in Clinical-Stage Programs |
| August 28 |
Inflazyme Pharmaceuticals Does Not Exercise Option with Helicon
Therapeutics to PDE4 Inhibitor, IPL455,903, in Learning and Memory
Disorders |
| August 29 |
Court Rules That Roche Infringes One of Amgen's Erythropoietin
Patents |
| August 29 |
PDL BioPharma Announces Significant Strategic and Portfolio Changes
to Focus on Antibody Discovery and Development |
| August 29 |
MGI Pharma Signs Agreement for Rights to Novel Treatment for
Thrombocytopenia |
| August 29 |
Merck Serono to Reconsider Development of Matuzumab in Metastatic
Colorectal Cancer Patients |
| August 29 |
Immunicon Announces Laboratory Services and Assay Development
Agreements with Merck Serono |
| August 29 |
National Asthma Guidelines Updated |
| August 29 |
IMS Health, Wolters Kluwer Health and Verispan Challenge State Laws
Restricting Access to Critical Healthcare Information |
| August 30 |
Lilly and Takeda to Terminate Joint Development/Co-Marketing
Agreement on Ruboxistaurin mesylate, An Agent for the Treatment of
Diabetes Microvascular Complications |
| August 30 |
King Pharmaceuticals and Palatin Technologies Delay Immediate Plans
for Phase 3 Clinical Program With Bremelanotide for Erectile
Dysfunction |
| August 30 |
GSK Supports Emphasis on Asthma Control and Use of Quick Assessment
Tools in New Asthma Treatment Guidelines |
| August 30 |
Cardiome And Astellas Announce Regulatory Extension |
| August 30 |
Paion's Partner Forest Terminates Co-Development on Desmoteplase |
| August 30 |
Pfizer Proves It Can Do More with Lipitor - Protecting Vital Access
to Patients at the Heart of Winning Managed Care Strategy |
| August 31 |
Mylan Commences Tender Offers and Consent Solicitations for Its
5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in
Connection With Its Proposed Acquisition of Merck's Generic
Pharmaceutical Business |
| August 31 |
Boehringer Ingelheim Voluntarily Withdraws Its Clobutinol
Containing Medications |
| August 31 |
AstraZeneca and Abbott Announce Selection of Next-Generation
Fenofibrate (ABT-335) and Crestor Fixed-Dose Combination |
